Botulinum toxin (보톡스).

Allergan's Botox (US) is available and the most expensive. The Korean domestic brands dominate by volume: Nabota (나보타), Meditoxin (메디톡신), Botulax (보툴렉스), and Coretox (코어톡스). They are the same active molecule with different manufacturing processes and (for some) different KFDA approval histories. Ask which brand is used and why.

Forehead, glabella (between the brows), crow's feet, bunny lines, lip flip, masseter (jawline narrowing), calves (leg contour), and trapezius (shoulder line). The non-facial applications are distinctly Korean — most Western clinics don't offer them routinely.

Brand, unit count, pricing per area, and the clinic's policy on top-ups if the effect is weaker than expected after 2 weeks. Many Korean clinics will top up at no charge within a defined window — confirm before you pay.

None. Small injection marks fade within hours. Full effect at 10–14 days; duration 3–4 months facial, 4–6 months masseter and larger muscle groups.

Forehead + glabella combo: ₩100,000–₩300,000. Crow's feet: ₩80,000–₩200,000. Masseter: ₩200,000–₩500,000. Calf botox: ₩400,000–₩800,000. Trapezius: ₩300,000–₩700,000. Allergan Botox adds roughly 50–100% over domestic brand pricing.

"How many units are you recommending and what's your dose range for this area?" A clinic that over-doses to produce a dramatic effect risks muscle atrophy or asymmetric loss. A clinic that under-doses to keep you coming back isn't serving you either. The right answer is specific and technical.

Most botulinum toxin (보톡스) sessions in Korean clinics are brisk, quiet appointments. After a brief consultation and a photograph for the record, the injector cleans the area with alcohol, marks injection points with a fine skin pencil, and often hands over an ice pack to numb the skin for a minute or two. No general or local anesthesia is required. Some clinics apply a topical numbing cream for masseter or trapezius work, but most facial injections proceed without it. The needle itself is very fine — 30 to 32 gauge — and each injection point delivers a small volume in under a second.

Patients usually receive 4 to 8 injections per area: forehead, glabella (미간), crow's feet, masseter, or shoulder line, depending on the plan. The sensation is a quick sting at each point, sometimes described as a rubber band snap, followed by mild pressure as the product diffuses. The whole procedure rarely lasts more than 15 minutes from sit-down to stand-up. There is no downtime in the conventional sense — small red marks at injection points fade within 30 to 60 minutes, and most patients return to work or errands the same hour, sometimes with a light dusting of mineral powder.

What patients underestimate is the timeline of the result, not the procedure. Day 0 looks unchanged. Day 3 brings the first softening of movement; by then, raising the eyebrows or frowning feels lighter. Day 7 is the inflection point — most of the muscle relaxation is visible. Peak effect arrives at day 14, which is also when reputable clinics schedule the touch-up window. The Korean rhythm is patient: results are not rushed, and adjustments are made at the 2-week mark rather than on the day.

Botulinum toxin type A has one of the longest published safety records in aesthetic medicine, and the Korean-developed products have been studied head-to-head against the Western reference, Allergan's onabotulinumtoxinA. A multicenter, double-blind, randomized trial of DWP450 — the molecule sold in Korea as Nabota (나보타) and globally as Jeuveau — versus onabotulinumtoxinA in 268 patients with glabellar lines (PMID: 25311357) reported a responder rate of 93.89% for the Korean product versus 88.64% for Allergan's, and concluded non-inferiority with comparable adverse event profiles. A larger Phase III non-inferiority study of prabotulinumtoxinA (Nabota/Jeuveau) versus onabotulinumtoxinA in 540 European and Canadian patients (PMID: 30951166) reached the same conclusion at the standard 20-unit glabellar dose. Meditoxin/Neuronox (메디톡신) has its own published non-inferiority data against Botox at 1:1 dosing in 314 patients aged 20 to 65.

On adverse events, eyelid ptosis (눈꺼풀 처짐) is the most-cited clinically relevant complication of glabellar injection. Published rates vary from 1% in well-controlled randomized trials to approximately 0.9% in large open-label safety studies of prabotulinumtoxinA (PMID: 33944913), with rates declining across successive treatment cycles as injectors refine technique. Headache, transient brow heaviness, and dry mouth are the next most commonly reported events, all typically self-limited within days to weeks.

The longer-term concern is immunogenicity. A systematic review and meta-analysis across therapeutic indications (PMID: 33528495) and a second meta-analysis of neutralizing antibodies in botulinum toxin therapy (PMID: 26467676) place neutralizing antibody (NAb) incidence at roughly 0.5% to 1.8% across formulations and indications, with higher cumulative dose and shorter inter-treatment intervals associated with increased risk. Korean newer-generation products such as Coretox (코어톡스) and Innotox (이노톡스) are formulated without complexing proteins specifically to lower this theoretical risk; long-term comparative aesthetic data remain in development. None of these numbers replace a personal pre-treatment discussion. Ask your injector which brand they default to, why, and what their own reported rates of ptosis and secondary non-response look like.

Botulinum toxin softens muscle pull. That single mechanism explains what it can and cannot do. On the upper face, it reduces the frontalis pull that creates horizontal forehead lines, the corrugator and procerus pull that produces the glabellar 11s (미간주름), and the orbicularis oculi pull responsible for crow's feet (눈가주름). On the lower face, masseter injection (턱보톡스) reduces the bulk of the chewing muscle over 4 to 6 weeks, which narrows the visible jaw silhouette — the so-called V-line by tox. On the body, trapezius injection (어깨보톡스) reduces upper-shoulder muscle volume to lengthen the visual neck-to-shoulder line, and calf injection slims the gastrocnemius for the lower leg. Microbotox or skin-tox (스킨보톡스) is a separate technique: very diluted toxin injected superficially across the cheeks and forehead to reduce sebaceous and sweat-gland activity, tightening pores without paralyzing expression.

What it does not do is equally important. It does not fill volume loss — static lines from collagen depletion, tear troughs, and hollowed cheeks are filler or biostimulator territory. It does not lift sagging skin; that work belongs to thread lift, HIFU, or surgery. It does not change skin texture, pigmentation, or scar appearance. And it does not treat the underlying bone or fat pads that define face shape. A 25 to 30 year old patient is usually approaching botulinum toxin preventatively, with low doses on early dynamic lines and selective masseter work; a 35-plus patient more often combines tox with skin boosters or fillers, because by that point the contributors to facial aging are layered rather than purely muscular. The right plan reflects which layer is actually driving what you see.

Long-term efficacy and outcome data for cosmetic botulinum toxin are well established. A meta-analysis of duration of effect for glabellar lines (PMID: 23106853) concluded that 20 units of onabotulinumtoxinA delivers sustained clinical benefit in more than 50% of responders at 4 months, with median duration around 14 weeks and a small subset of responders maintaining effect well beyond 6 months. Higher doses extend duration but do not eliminate the eventual return of movement; the Korean clinical preference for moderate dosing with more frequent visits reflects this reality.

On comparative trials, the equivalence literature for Korean products versus Allergan's reference toxin is consistent across multiple Phase III studies. The Daewoong DWP450 study (PMID: 25311357) and the multicenter prabotulinumtoxinA non-inferiority trial (PMID: 30951166) form the backbone of the regulatory data that carried Nabota through US FDA and European approval as Jeuveau and Nuceiva, respectively.

On patient-reported outcomes, the FACE-Q aesthetic module is now the standard validated instrument. A FACE-Q study of botulinum toxin neuromodulation of the glabellar region (PMID: 26780945) documented a 28% increase in satisfaction with overall facial appearance and patients reporting an average perceived age reduction of 5.6 years post-injection. A systematic review of patient-reported outcomes for cosmetic botulinum toxin indications (PMID: 30893170) reported satisfaction rates ranging from 65% to more than 90%, varying by area, dose, and assessment timing.

On masseter work specifically, a randomized double-blind placebo-controlled dose-finding study of prabotulinumtoxinA (PMID: 33347002) treated 90 Korean subjects across 24, 48, 72, and 96-unit groups; masseter thickness reduced significantly versus placebo at 12 weeks, with dose-dependent effects measured by ultrasound and 3D imaging. Diffusion radius differs across formulations — incobotulinumtoxinA and Coretox-type purified toxins are reported to diffuse less than older complex-protein formulations, which is why Korean injectors often discuss brand choice in the context of how delicate the area is. Ask your injector to walk through their product selection logic; a clear answer is a useful filter.

Korean botulinum toxin practice in 2026 is defined by lower doses, more frequent visits, and a wider range of off-label body uses than Western practice. Korean botox (한국 보톡스) searches now drive significant inbound traffic to Gangnam clinics, partly because the domestic brands — Nabota (나보타), Innotox (이노톡스), Meditoxin (메디톡신), Botulax, and Coretox (코어톡스) — have built international recognition through Phase III equivalence data and visible export growth. Innotox in particular is the world's first ready-to-use liquid toxin and removes the dilution variability that explains some of the dose inconsistency between clinics.

Skin botox or microbotox (스킨보톡스) has shifted from niche to mainstream, with Gangnam dermatology clinics offering it as a pore-tightening and oil-reducing surface treatment delivered by very diluted intradermal injections across the cheeks, forehead, and along the jawline. Calf botox (종아리보톡스) and shoulder line or trapezius botox (어깨보톡스) remain distinctly Korean — most Western clinics do not offer them routinely, and Korean searches for both spike around wedding season and graduation photos.

Around the procedure, recovery and skin-quality add-ons have expanded. PDRN (polydeoxyribonucleotide) injectables and topicals, derived from salmon DNA, are routinely paired with skin botox and with post-tox skin recovery in many Gangnam clinics. The glass skin endpoint — clear, light-reflecting skin — frames how the result is judged: Korean patients are looking for softened expression with retained micro-movement, not a frozen face. Exosome facials (엑소좀) are increasingly offered as adjuncts post-treatment; published evidence in this specific indication remains early, and patients should ask whether the clinic uses regulated, traceable exosome products. The Korean preference is consistently the same: lower units, more dose adjustment over time, lower risk of an overdone result.

How often do I need to come back? Most patients return every 3 to 4 months for facial areas and every 4 to 6 months for masseter, calf, and trapezius. Korean clinics often suggest a 2-week touch-up review after the first session; many include it in the original fee.

Can I drive home after? Yes. There is no sedation, no anesthesia, and no impairment of vision or coordination. Most patients drive, use public transport, or return to work the same hour.

Will I look frozen? Not at standard Korean dosing, which favours softened movement over full paralysis. A frozen look usually comes from over-dosing or from injecting a flat plane across the forehead without preserving the lateral lift. Discuss with your injector whether they aim for full immobilisation or controlled softening, and ask to see un-retouched results.

Can I exercise after? Most clinics ask you to avoid intense cardio, hot yoga, saunas, and lying flat for 4 to 6 hours after injection, to limit theoretical product migration. Light walking and normal daily movement are fine immediately.

Is it safe during pregnancy or breastfeeding? Cosmetic botulinum toxin is not recommended during pregnancy or breastfeeding. Reputable Korean clinics will postpone treatment until after weaning. Ask your provider for their written policy.

What if I do not like the result — can it be reversed? Botulinum toxin cannot be dissolved the way hyaluronic acid filler can. The effect simply wears off as the muscle recovers, typically over 3 to 4 months. This is one reason injectors err toward conservative dosing on the first visit.

Will my body build resistance to it? A small percentage of patients (roughly 0.5% to 1.8% across published meta-analyses) develop neutralizing antibodies that reduce response over time. Risk is associated with frequent injections at high cumulative doses. Switching to a complex-protein-free formulation such as Coretox or Innotox is one strategy your provider may discuss.

Can I see a preview before committing? Not in the way fillers can be previewed. Botulinum toxin acts on muscle over days, so the only honest preview is the dose itself. Some Korean clinics start with a conservative half-dose at the first visit and add more at the 2-week review.

Is masseter botox safe for chewing? Standard masseter dosing reduces bulk while preserving function; most patients notice no change in chewing capacity for normal foods. Very tough foods may feel slightly more effortful in the first 2 to 4 weeks. Discuss your dose with your injector if you have a history of TMJ discomfort.

Are Korean toxin brands as good as Botox or Allergan? Published Phase III equivalence data for Nabota/prabotulinumtoxinA (PMID: 30951166) and DWP450 (PMID: 25311357) show non-inferiority versus onabotulinumtoxinA at standard glabellar dosing, with comparable safety profiles. Brand choice in Korean clinics is often a function of price, formulation preference, and clinician familiarity rather than efficacy. Ask which brand the clinic uses and why.